Actively Recruiting

Phase Not Applicable
Age: 50Years - 69Years
All Genders
ID06799793

Artificial Intelligence-Based Screening Models for Personalized Prevention and Early Detection of Colorectal Cancer

Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-01-29

1400

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating new personalized colorectal cancer (CRC) screening methods using artificial intelligence (AI) to improve early detection. Colorectal cancer is a common and deadly disease, with risk factors including age, obesity, smoking, diet, and physical activity. This study aims to develop a predictive risk model to tailor screening strategies, moving from a one-size-fits-all approach to personalized prevention by integrating AI and patient risk profiles. Participants will undergo colonoscopy either with traditional methods or with AI assistance using the GI Genius device to help detect colorectal lesions. Those testing positive for fecal occult blood through a regional screening program will be randomized to receive either standard colonoscopy or AI-assisted colonoscopy. Data on diet, physical activity, and other risk factors will also be collected through questionnaires. Follow-up colonoscopies may be scheduled based on findings at 1, 3, or 5 years. Participants will be involved in interviews, receive preparation instructions, complete questionnaires, and undergo colonoscopy according to their assigned group. The study will monitor adenoma detection rates and other outcomes over 18 months, with a total study duration of 72 months. Researchers will analyze data to improve screening precision and reduce unnecessary invasive procedures, aiming to optimize screening pathways based on individual risk.

CONDITIONS

Brief Title

Artificial Intelligence-based Screening Models for Prevention and Early Detection of Colorectal Cancer

Who Can Participate

Age: 50Years - 69Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Subjects aged 50-69 years who underwent the fecal occult blood screening program
  • Male and female sex
  • Positive fecal occult blood test (FIT) result on immunochemical screening (OC-Sensor) with a cut-off of 20 micrograms HgB/gr of stool
  • Provided written consent to participate in the study
Not Eligible

You will not qualify if you...

  • Do not understand the Italian language
  • Previous history of total colectomy or bowel resections
  • Colonoscopy performed in the previous 12 months
  • Contraindications to colonoscopy
  • Contraindications to sedation or anesthesia
  • Personal history of colorectal cancer
  • Hereditary gastrointestinal cancer syndromes such as familial adenomatous polyposis (FAP), attenuated FAP, MutYH-associated polyposis, Lynch or Lynch-like syndrome, and serrated polyposis syndrome
  • Inflammatory bowel disease including Crohn's disease and ulcerative colitis

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Diagnostic Evaluation

Duration - Up to 1 month

Participants who tested positive for fecal occult blood test undergo a telephone interview and outpatient clinic visits for prescription, bowel preparation, and questionnaires on diet and physical activity before colonoscopy.

1 telephone interview and 2 outpatient clinic visits (in-person)

Colonoscopy

Duration - 1 day

Participants are randomized to receive either traditional colonoscopy or colonoscopy with artificial intelligence assistance to detect colorectal lesions.

1 outpatient clinic visit (in-person) for colonoscopy and questionnaire submission

Follow-up

Duration - Up to 5 years

Participants with detected polyps or suspicious lesions may have follow-up colonoscopies at 1, 3, or 5 years depending on clinical findings to optimize screening pathways.

1 to 3 outpatient visits depending on clinical needs

Trial Site Locations

Total: 1 location

1

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, Bologna, Italy, 40138

Actively Recruiting

Loading map...

Research Team

G

Giovanni Barbara, MD

C

Chiara Pierantoni, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SCREENING

Number of Arms

2

Similar Trials

A Phase 1/2a Study of the Safety, Tolerability, and Prelimin...

Castration-Resistant Prostate Cancer (CRPC)

Actively Recruiting

4 locations

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

A Phase 1/2a Study Utilizing 64Cu-LNTH-1363S (64Cu Radiolabe...

Metastatic Sarcoma

Actively Recruiting

5 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here